[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340061-105":59,"doc-detail-340061-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","synergistic-cytotoxicity-of-histone-deacetylase-and-poly-adp-ribose-polymerase-inhibitors-and-decitabine-in-breast-and-ovarian-cancer-cells-implications-for-novel-therapeutic-combinations","Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells - Implications for Novel Therapeutic Combinations","","Breast and ovarian cancers pose significant therapeutic challenges. The study evaluates the synergistic cytotoxicity of histone deacetylase inhibitors (HDACis), poly(ADP-ribose) polymerase inhibitors (PARPis), and decitabine in breast (MDA-MB-231, MCF-7) and ovarian (HEY-T30, SKOV-3) cancer cell lines. HDACi, PARPi, and decitabine combinations show synergistic cytotoxicity (combination index \u003C 1) with reduced proliferation, increased Annexin V positivity, PARylation inhibition, PARP1 and caspase 3 cleavage, and c-MYC down-regulation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/synergistic-cytotoxicity-of-histone-deacetylase-and-poly-adp-ribose-polymerase-inhibitors-and-decitabine-in-breast-and-ovarian-cancer-cells-implications-for-novel-therapeutic-combinations/340061/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/synergistic-cytotoxicity-of-histone-deacetylase-and-poly-adp-ribose-polymerase-inhibitors-and-decitabine-in-breast-and-ovarian-cancer-cells-implications-for-novel-therapeutic-combinations/340061.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which cancer cell lines were used to test the three-drug combinations?","Question",{"text":112,"@type":113},"The combinations were tested in breast cancer cell lines MDA-MB-231 and MCF-7, and ovarian cancer cell lines HEY-T30 and SKOV-3.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What assays demonstrated synergistic cytotoxicity?",{"text":117,"@type":113},"Synergistic cytotoxicity was assessed using MTT and clonogenic assays, with combination indices \u003C 1 across all tested cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"What molecular effects were observed after treatment with the combined therapies?",{"text":121,"@type":113},"Western blot results showed inhibition of PARylation, cleavage of c-MYC-related and DNA-repair-associated proteins (caspase 3 and PARP1), DNA damage marked by increased phosphorylation of histone 2AX, impaired DNA repair pathways, and altered epigenetic gene regulation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340061,1790801722,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nSynergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel  \nTherapeutic Combinations  \nBenigno C. Valdez 1, Apostolia M. Tsimberidou 2, *, Bin Yuan 1, Mehmet A. Baysal 2, Abhijit Chakraborty 2, Clark R. Andersen 3 and Borje S. Andersson 1  \nCitation: Valdez, B.C.; Tsimberidou, A.M.; Yuan, B.; Baysal, M.A.;  \nChakraborty, A.; Andersen, C.R.; Andersson, B.S. Synergistic Cytotoxicity of Histone Deacetylaseand Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells:  \nImplications for Novel Therapeutic Combinations. Int. J. Mol. Sci. 2024, 25, 9241. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25179241  \nAcademic Editor: Erik A.C. Wiemer  \nReceived: 21 July 2024  \nRevised: 13 August 2024  \nAccepted: 14 August 2024  \nPublished: 26 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA  \n2 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; [achakraborty3@mdanderson.org](achakraborty3@mdanderson.org) (A.C.)  \n3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \n* Correspondence: [atsimber@mdanderson.org](atsimber@mdanderson.org); Tel.: +1-713-792-4259; Fax: +1-713-794-3249  \nAbstract: Breast and ovarian cancers pose significant therapeutic challenges. We explored the synergistic cytotoxicity of histone deacetylase inhibitors (HDACis), poly(ADP-ribose) polymerase inhibitors (PARPis), and decitabine in breast (MDA-MB-231 and MCF-7) and ovarian (HEY-T30 and SKOV-3) cancer cell lines that were exposed to HDACi (panobinostat or vorinostat), PARPi (talazoparib or olaparib), decitabine, or their combinations. HDACi, PARPi, and decitabine combinations had synergistic cytotoxicity (assessed by MTT and clonogenic assays) in all cell lines (combination index \u003C 1) . Clonogenic assays confirmed the sensitivity of breast and ovarian cancer cell lines to the three-drug combinations (panobinostat, talazoparib, and decitabine; panobinostat, olaparib, and decitabine; vorinostat, talazoparib, and decitabine; vorinostat, olaparib, and decitabine) . Cell proliferation was inhibited by 48–70%, and Annexin V positivity was 42–59% in all cell lines exposed to the three-drug combinations. Western blot analysis showed protein PARylation inhibition, caspase 3 and PARP1 cleavage, and c-MYC down-regulation. The three-drug combinations induced more DNA damage (increased phosphorylation of histone 2AX) than the individual drugs, impaired the DNA repair pathways, and altered the epigenetic regulation of gene expression. These results indicate that HDACi, PARPi, and decitabine combinations should be further explored in these tumor types. Further clinical validation is warranted to assess their safety and efficacy.  \nKeywords: breast cancer; ovarian cancer; HDAC inhibitors; PARP inhibitors; decitabine; DNA repair; synergistic cytotoxicity  \n1. Introduction  \nBreast and ovarian cancers are major contributors to cancer-related mortality in women worldwide, highlighting the urgent need for novel therapeutic strategies to combat resistance and improve patient outcomes [1] . The American Cancer Society estimates that in the United States, 310,720 new cases of invasive breast cancer will be diagnosed in women in 2024, along with an additional 56,500 new cases of ductal car","cbCaiuQvJedgTtkc","https://ap.wps.com/l/cbCaiuQvJedgTtkc","pdf",2815995,16,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"Which cancer cell lines were used to test the three-drug combinations?\",\"answer\":\"The combinations were tested in breast cancer cell lines MDA-MB-231 and MCF-7, and ovarian cancer cell lines HEY-T30 and SKOV-3.\"},{\"question\":\"What assays demonstrated synergistic cytotoxicity?\",\"answer\":\"Synergistic cytotoxicity was assessed using MTT and clonogenic assays, with combination indices \\u003c 1 across all tested cell lines.\"},{\"question\":\"What molecular effects were observed after treatment with the combined therapies?\",\"answer\":\"Western blot results showed inhibition of PARylation, cleavage of c-MYC-related and DNA-repair-associated proteins (caspase 3 and PARP1), DNA damage marked by increased phosphorylation of histone 2AX, impaired DNA repair pathways, and altered epigenetic gene regulation.\"}]","Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells - Implications for Novel Therapeutic Combinations | PDF",1790033992,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34c0dbb8b1a0772a8c6f1d877afec85d.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6cb7ca9aed92860875e1893de2a2bb0.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/196c7e9025f76de975ce075226ce65f8.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcb1391881e00598211e5684310b0672.webp",980,1385]